Omnicell (NASDAQ:OMCL) Sets New 52-Week Low at $92.82

Omnicell, Inc. (NASDAQ:OMCLGet Rating)’s share price hit a new 52-week low during mid-day trading on Monday . The company traded as low as $92.82 and last traded at $92.83, with a volume of 907 shares. The stock had previously closed at $95.27.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Piper Sandler dropped their price objective on Omnicell from $162.00 to $150.00 and set an “overweight” rating on the stock in a research note on Monday, August 8th. Bank of America began coverage on Omnicell in a report on Friday, September 9th. They set a “buy” rating and a $120.00 target price on the stock. KeyCorp began coverage on Omnicell in a report on Thursday, September 15th. They set an “overweight” rating and a $130.00 target price on the stock. BTIG Research decreased their target price on Omnicell from $190.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, July 27th. Finally, SVB Leerink began coverage on Omnicell in a report on Friday, July 15th. They set a “market perform” rating and a $124.00 target price on the stock. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $151.71.

Omnicell Trading Down 3.3 %

The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.71 and a current ratio of 2.11. The business has a fifty day simple moving average of $106.32 and a 200 day simple moving average of $114.53. The stock has a market capitalization of $3.98 billion, a price-to-earnings ratio of 71.37, a price-to-earnings-growth ratio of 2.65 and a beta of 1.06.

Omnicell (NASDAQ:OMCLGet Rating) last released its earnings results on Thursday, August 4th. The company reported $0.84 earnings per share for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.01). Omnicell had a net margin of 4.82% and a return on equity of 10.37%. The company had revenue of $331.39 million for the quarter, compared to the consensus estimate of $339.45 million. During the same quarter in the previous year, the company posted $0.71 earnings per share. The business’s revenue was up 21.5% compared to the same quarter last year. As a group, research analysts expect that Omnicell, Inc. will post 2.7 EPS for the current year.

Insider Buying and Selling

In related news, CFO Peter J. Kuipers sold 11,000 shares of the company’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $105.93, for a total transaction of $1,165,230.00. Following the completion of the sale, the chief financial officer now directly owns 61,326 shares in the company, valued at approximately $6,496,263.18. The sale was disclosed in a filing with the SEC, which is available through this link. In other Omnicell news, CFO Peter J. Kuipers sold 11,000 shares of the stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $105.93, for a total value of $1,165,230.00. Following the completion of the transaction, the chief financial officer now directly owns 61,326 shares in the company, valued at $6,496,263.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Randall A. Lipps sold 13,000 shares of the stock in a transaction dated Tuesday, August 16th. The shares were sold at an average price of $111.04, for a total value of $1,443,520.00. Following the completion of the transaction, the chief executive officer now owns 302,049 shares of the company’s stock, valued at $33,539,520.96. The disclosure for this sale can be found here. Insiders sold a total of 39,500 shares of company stock worth $4,287,245 in the last ninety days. 2.76% of the stock is owned by insiders.

Hedge Funds Weigh In On Omnicell

Large investors have recently bought and sold shares of the company. Raymond James & Associates raised its position in Omnicell by 8.9% in the first quarter. Raymond James & Associates now owns 128,877 shares of the company’s stock valued at $16,688,000 after purchasing an additional 10,487 shares during the last quarter. Swiss National Bank increased its stake in shares of Omnicell by 8.6% in the first quarter. Swiss National Bank now owns 103,900 shares of the company’s stock valued at $13,454,000 after buying an additional 8,200 shares during the period. Lindenwold Advisors acquired a new stake in shares of Omnicell in the fourth quarter valued at about $377,000. Capital Fund Management S.A. acquired a new stake in shares of Omnicell in the first quarter valued at about $1,392,000. Finally, Handelsbanken Fonder AB increased its stake in shares of Omnicell by 27.9% in the first quarter. Handelsbanken Fonder AB now owns 9,623 shares of the company’s stock valued at $1,246,000 after buying an additional 2,100 shares during the period.

Omnicell Company Profile

(Get Rating)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Further Reading

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.